Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
OPKO Health, Inc. - SIC # 8071 - MEDICAL LABORATORIES
Ticker
Exchange
SIC #
Website
Latest Ticker
OPK
Nasdaq
8071
www.opko.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for OPKO Health, Inc.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
- May 21st, 2026 10:23 am
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
- May 12th, 2026 6:00 am
Spotlight On Promising Penny Stocks For May 2026
- May 11th, 2026 12:05 pm
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
- Apr 30th, 2026 6:30 am
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
- Apr 30th, 2026 6:00 am
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y
- Apr 29th, 2026 10:58 am
OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ...
- Apr 29th, 2026 1:09 am
OPKO Health Q1 Earnings Call Highlights
- Apr 28th, 2026 5:39 pm
OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
- Apr 28th, 2026 5:00 pm
OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
- Apr 28th, 2026 5:00 pm
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
- Apr 28th, 2026 2:05 pm
How The OPKO Health (OPK) Narrative Is Shifting After Mixed Results And A Lower Price Target
- Apr 23rd, 2026 12:04 pm
Here's Why You Should Hold OPK Stock in Your Portfolio for Now
- Apr 23rd, 2026 10:07 am
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
- Apr 22nd, 2026 6:00 am
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
- Apr 21st, 2026 2:05 pm
OPKO Health, Inc. (OPK) Makes Progress on Game changing Covid-19 Treatment
- Apr 14th, 2026 3:55 am
OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
- Apr 8th, 2026 6:00 am
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
- Mar 27th, 2026 2:05 pm
How The OPKO Health (OPK) Story Is Shifting With Mixed Analyst Signals
- Mar 27th, 2026 12:08 pm
Barrington Lowers PT on OPKO Health (OPK), Keeps a Buy
- Mar 20th, 2026 4:08 pm
Scroll